Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis Kehui LiuMingyang FengHui Wang Original Article Open access 09 September 2024
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN) Bikrant Bihari LalRajeev KhannaShiv Kumar Sarin Guidelines 30 August 2024
Letter to the editor to ‘‘Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases’’ Bihua YaoJianguo Wu Letter to the Editor 29 August 2024
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD Mingqian JiangZiyan PanMohammed Eslam Original Article 28 August 2024
“Cherry blossom” in Kyoto brought hope to patients with chronic hepatitis B infection Jing ChenJi-Dong JiaOn behalf of APASL Viral Elimination Taskforce (in no particular order) Point-of-View Open access 27 August 2024
Is laparoscopic hepatectomy superior to radiofrequency ablation in treating small hepatocellular carcinoma? Dali XiongJiaran LiShuanghu Yuan Letter to the Editor 27 August 2024
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis Xiaofei TongYameng SunHong You Original Article 16 August 2024
Mesenchymal stem cells-derived exosomes alleviate liver fibrosis by targeting Hedgehog/SMO signaling Ruobin ZongYan ZhengChangyong Li Original Article 13 August 2024
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis Huilian ShiXiangtao XuFei Qiao Original Article 12 August 2024
Acute presentation of autoimmune hepatitis –from acute hepatitis to ALF and ACLF- Atsushi TanakaKenichi Harada Review Article 11 August 2024
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer Dongming LiuWenshuai ChenHua Guo Original Article Open access 10 August 2024
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals Matheus SouzaIvanna DiazLubna Al-Sharif Review Article 08 August 2024
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD Chun-Jen LiuWai Kay SetoMing-Lung Yu Special supplement : MAFLD 08 August 2024
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier Ashok ChoudhuryRuveena RajaramShiv Kumar Sarin Special supplement : MAFLD 06 August 2024
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents Piyush UpadhyayRajeev KhannaSeema Alam Original Article 29 July 2024
Metabolic dysfunction associated fatty liver disease in healthy weight individuals Nahum Méndez-SánchezWillem Pieter BrouwerYusuf Yilmaz Special supplement : MAFLD Open access 25 July 2024
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study Yuyu ZengDakai GanMolong Xiong Original Article 20 July 2024
Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B Chi ZhangYiqi LiuChina HepB-Related Fibrosis Assessment Research Group Original Article Open access 17 July 2024
Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation Jihye LimSung-Eun KimThe Korean Acute on Chronic Liver Failure (KACLiF) Study GroupA, on behalf of the Korean Acute-on-Chronic Liver Failure (KACLiF) Study Group Original Article 17 July 2024
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients Maria Eva ArgenzianoMi Na KimGianluca Svegliati Baroni Special supplement : MAFLD 16 July 2024
NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia Karl VazWilliam KempStuart K. Roberts Original Article Open access 15 July 2024 Pages: 1135 - 1143
Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group Tommaso Maria ManziaBarbara Antonellion behalf of the Italian Liver Transplant Working Group Review Article Open access 15 July 2024
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma Zhaoxian LiYumeng ZhaoWentao Jiang Original Article 14 July 2024
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact Anna AlisiGeoffrey McCaughanHenning Grønbæk Special supplement : MAFLD 12 July 2024
Chinese guidelines on the management of ascites in cirrhosis Xiaoyuan XuHuiguo DingHui Zhuang Guidelines 09 July 2024 Pages: 1071 - 1089
Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis Bastian EngelJana DiestelhorstRichard Taubert Original Article Open access 08 July 2024 Pages: 1214 - 1226
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning Hiroshi ImamuraKatsuhiro SanoAkio Saiura Editorial 08 July 2024
Reply to: “Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed” Zhen-Xin ZengJia-Yi WuMao-Lin Yan Letter to the Editor 08 July 2024
Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease Yasser FouadMohamed AlboraieGamal Shiha Special supplement : MAFLD Open access 05 July 2024
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis Gui-Ji LvDong JiOn behalf of APASL Viral Elimination Task force Original Article 05 July 2024
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma Makoto ChumaHaruki UojimaShin Maeda Original Article 04 July 2024
Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma Mengxuan ZuoYuzhe CaoWang Li Original Article Open access 03 July 2024
Treating extrahepatic portal-vein obstruction with cavernoma using radiological interventions: pushing the boundaries Amar MukundRichard Moreau Editorial 02 July 2024 Pages: 1093 - 1095
Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics Nan ZhangZhaohui LiHanping Wang Original Article Open access 02 July 2024
Inflammation of the liver, HCC development and HCC establishment Tatsuo KandaReina Sasaki-TanakaShuji Terai Editorial 28 June 2024 Pages: 1090 - 1092
The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients Xindan HuYing Wen Letter to the Editor Open access 27 June 2024 Pages: 1338 - 1339
Response to the letter of HEPI-D-24–00252 Shang-Chin HuangTung-Hung SuJia-Horng Kao Letter to the Editor 26 June 2024 Pages: 1340 - 1341
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis Pei-Xin ZhangQian-Qian TangZhen-Hua Zhang Original Article 24 June 2024 Pages: 1110 - 1121
MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD Wah-Kheong ChanVincent Wai-Sun WongMindie H. Nguyen Special supplement : MAFLD 24 June 2024
Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation Mohammad AlarabiZiyan PanMohammed Eslam Original Article 20 June 2024
Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome Masanori OshiKohei ChidaKazuaki Takabe Original Article 19 June 2024 Pages: 1299 - 1309
Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002–2022 Simiao YuJiahui LiRuilin Wang Original Article Open access 19 June 2024 Pages: 1202 - 1213
Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease Shifan QinXiang ChengZhiqian Yi Original Article 18 June 2024 Pages: 1158 - 1167
MAFLD: from a disease framework to patient care Mohammed EslamJacob George Special supplement : MAFLD Open access 17 June 2024
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives Sunitha VimalesvaranPietro VajroAnil Dhawan Special supplement : MAFLD Open access 16 June 2024
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease Huai ZhangGiovanni Targheron behalf of the MAFLD ICD-11 coding collaborators Original Article 15 June 2024 Pages: 1178 - 1201
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease Robert GishJian-Gao FanJerome Boursier Special supplement : MAFLD 08 June 2024
Hepatic-associated vascular morphological assessment to predict overt hepatic encephalopathy before TIPS: a multicenter study Xiaoqiong ChenMingsheng HuangSirui Fu Original Article Open access 04 June 2024 Pages: 1238 - 1248
HBeAg induces neutrophils activation impairing NK cells function in patients with chronic hepatitis B Zhiqian FengJunliang FuFu-Sheng Wang Original Article 03 June 2024 Pages: 1122 - 1134
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study So Hyun ChoSeohyun KimJae Hyeon Kim Original Article 28 May 2024 Pages: 1168 - 1177
